Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LR-GEM versus R-GEM-P in relapsed or refractory diffuse large B-cell lymphoma
2012-002620-32Phase 2Unknown
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Feb 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lenalidomide, rituximab, gemcitabine, methylprednisolone and cisplatin in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoint: Complete response rate after 3 cycles of induction treatment. Status: unknown.
02
Drugs
lenalidomiderituximabgemcitabinemethylprednisolonecisplatin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2012-002620-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002620-32.